E. Marušáková
YOU?
Author Swipe
View article: Humoral immune response following the third dose of BNT162b2 received by employees at a Slovak cancer healthcare facility
Humoral immune response following the third dose of BNT162b2 received by employees at a Slovak cancer healthcare facility Open
BNT162b2 is a mRNA vaccine, approved by the US Food and Drug Administration and the European Medicines Agency that was designed to target Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus dise…